设为首页         

资讯内容 Content

[ESC2009]ACCOMPLISH研究的应用及影响--Düsing教授专访
国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

 编辑:国际循环网 时间:2009/9/3 18:26:00    加入收藏
 关键字:ACCOMPLISH Düsing 倍博特 阿利吉仑 


International Circulation: May I have your opinion about the position of SPC in antihypertensive therapy?

《国际循环》:请问您对SPC在抗高血压治疗中的地位如何看待?

Dr Dusing:  That is a difficult question. In Europe, where I come from, we do not have dual combination compounds for initial therapy, the only exception being an ACE inhibitor in combination with a diuretic both dosed very low. All other combinations, part of them already accepted for initial therapy in the US and some other countries, are not approved in Europe for initial therapy. I personally think initial therapy of stage 2 and 3 hypertension with dual compound SPC is probably a step in the right direction. It makes things easier, blood pressure control is established faster with fewer changes in therapy, and this may also affect long-term adherence with therapy.

Dusing教授:这是个很难回答的问题。在我所来自的欧洲,我们并没有将两种药物联合的复合药物用于初始治疗,惟一的例外是ACE抑制剂与利尿剂的极低剂量联合。在欧洲所有其他联合(其中一部分已在美国和一些其他的国家被接受用于初始治疗)均未获得批准用于初始治疗。我个人认为,两种药物联合的SPC用做2级和3级高血压的初始治疗很可能是向正确的方向迈出了一步。这使得事情变得更为简单,血压控制被证实更为迅速且治疗上的改变更少,而且,这可能也会影响长期的治疗依从性。



上一页  [1]  [2]  [3]  [4]  [5]  下一页

   评论发言          
 
京ICP备15014970号-5   国际循环 版权所有  2008-2022 icirculation.com  All Rights Reserved